THE EFFECTS OF HPV VACCİNATİON AND MESSAGE FRAMİNG
THE EFFECT OF GAIN AND LOSS FRAMING MESSAGES ON RISK PERCEPTION AND KNOWLEDGE LEVELS REGARDING HPV VACCINATION AMONG UNIVERSITY STUDENTS: A RANDOMIZED CONTROLLED TRIAL
Background: University students are at high risk for HPV infection, while HPV vaccination rates remain low. Message framing strategies may influence vaccination-related perceptions and intentions.
Objective: This study aims to compare the effects of gain- and loss-framed HPV vaccination messages on HPV risk perception, HPV knowledge, and vaccination intention among university students.
Methods: This randomized controlled experimental study includes university students from the health sciences faculty of a foundation university. Participants are assigned to gain-framed, loss-framed, and control groups. Data are collected using the Human Papillomavirus Knowledge Scale and the HPV Risk Perception Questionnaire. Statistical analyses include one-way ANOVA, two-way ANOVA, and Chi-square tests. The study is designed in accordance with CONSORT 2010 and EQUATOR Network reporting guidelines.
Keywords: message framing; gain-loss framing; human papillomavirus; vaccination
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This randomized controlled experimental study examines the effects of gain- and loss-framed HPV vaccination messages on university students' HPV knowledge, risk perception, and vaccination intention. A total of 927 university students were assigned to gain-framed, loss-framed, and control groups. The study evaluates the relationship between message framing and vaccination-related outcomes among university students.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Ankara
-
Ankara, Ankara, Turkiet (Türkiye), 06000
- Ankara Medipol Üniversitesi
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Aged 18 years or older
- Voluntarily agrees to participate in the study
- Has not received formal education about HPV through a course or class
Exclusion Criteria:
- Has received the HPV vaccine
- Has participated in formal education about HPV through a course or class
- Has a current or previous positive HPV test result or HPV diagnosis
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Gain-Framed Group
Participants received gain-framed HPV vaccination messages. |
Participants received gain-framed messages emphasizing the benefits of HPV vaccination. |
|
Experimentell: Loss-Framed Group
Participants received loss-framed HPV vaccination messages. |
Participants received loss-framed messages emphasizing the consequences of not receiving HPV vaccination. |
|
Inget ingripande: Control Group
Participants did not receive framed HPV vaccination messages. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
HPV Knowledge Level
Tidsram: Before intervention and immediately after message exposure
|
HPV knowledge level will be assessed using the Human Papillomavirus Knowledge Scale (HPVKS), a 33-item scale evaluating knowledge about HPV infection, screening tests, and vaccination. Total scores range from 0 to 33, with higher scores indicating higher HPV-related knowledge levels. |
Before intervention and immediately after message exposure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
HPV Risk Perception
Tidsram: Before intervention and immediately after message exposure
|
HPV risk perception will be assessed using a 10-item Likert-type HPV Risk Perception Questionnaire developed based on the literature and expert opinion. Total scores range from 0 to 40, with higher scores indicating higher perceived risk related to HPV infection and HPV-associated diseases. |
Before intervention and immediately after message exposure
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Patologiska processer
- Sjukdomsegenskaper
- Infektioner
- Virussjukdomar
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- DNA-virusinfektioner
- Tumörvirusinfektioner
- Patologiska tillstånd, tecken och symtom
- Beteende
- Behandlingsefterlevnad och efterlevnad
- Hälsobeteende
- Avslag på behandling
- Vaccinationsvägran
- Papillomavirusinfektioner
- Vaccinationstveksamhet
Andra studie-ID-nummer
- AMU-EBE-2025-173
- AMU-EBE-2025-173 (Annan identifierare: Ankara Medipol University Clinical Research Ethics Committee)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data will not be publicly shared in order to protect participant confidentiality and privacy.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .